Loading...
Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Lisa Ann Cavacini PhD

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Cavacini, Lisa

PropertyValue
overview

My laboratory focuses on humoral immunity, and human monoclonal antibodies (HMab) in particular, for infectious disease, cancer and autoimmune disease. A large number of HMab have been developed to study the structure/function of the HIV envelope protein with the immune system to inform active immunization strategies. HMab have also been used for passive immunotherapy in monkey models and clinical trials in humans, including the first trial of a human anti-HIV antibody.  Through the study of antibody diversity and engineering of HMab, we have demonstrated the preventative potential of anti-HIV IgA.  Antibody molecules are also being developed that can redirect immune cells to destroy HIV (bispecific antibodies).  HMab to a number of infectious disease targets, including bacteria and virus are being developed to follow the successful transfer of HMab to Pseudomonas aeruginosa and Staphylococcus aureus for clinical development.  Antibody molecules are also being designed to target siRNA to squamous cell carcinoma for treatment of head and neck cancer.  We have also begun to develop antibody molecules for vectored delivery.  Finally, we are developing protocols that result in affinity matured HMab in immunized humanized mice.  This model allows development of HMab to targets for which an in vivo response is either not possible or safe.  The laboratory has established itself as an important resource laboratory in the area of human monoclonal antibodies.  Not only has the research furthered our understanding of disease pathogenesis, but also has generated reagents used throughout the world. 


Search Criteria
  • Antibodies Bispecific